8-K current report · filed Jul 7, 2026

ResMed (RMD) 8-K Current Report: July 7, 2026

Item EX-99.1Item 2.02Item 7.01RMD overview

Short answer

ResMed (RMD) filed an 8-K current report with the SEC on July 7, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). MatrixCare sale to Frazier Healthcare Partners for $490 million cash, expected closing in fiscal Q1 2027.

ResMed 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • MatrixCare sale to Frazier Healthcare Partners for $490 million cash, expected closing in fiscal Q1 2027
  • MatrixCare contributed approximately $220 million revenue and $55 million non-GAAP operating profit in fiscal 2026
  • Net proceeds targeted for shareholder returns, including an accelerated share repurchase, and general corporate purposes
  • Noctrix acquisition expected to add approximately $30 million revenue but reduce fiscal 2027 non-GAAP diluted EPS by approximately $0.20
  • Residential Care Software outlook maintained at high-single-digit fiscal 2027 revenue growth with operating leverage

Item 7.01 · Regulation FD Disclosure

  • Item 7.01 incorporates the Item 2.02 earnings disclosure
  • Investor relevance depends on the earnings release and related financial results in Item 2.02

Item EX-99.1 · Exhibit EX-99.1

  • Definitive agreement to sell MatrixCare business to Frazier Healthcare Partners
  • Divestiture covers MatrixCare, Healthcare First, Citus, and home health and hospice software
  • MatrixCare serves more than 15,000 providers across post-acute and long-term care markets
  • Excludes ResMed’s Brightree and MEDIFOX DAN software businesses
  • Expected closing in ResMed’s fiscal Q1 2027, subject to regulatory approvals and customary conditions

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other ResMed 8-K filings

Get the next RMD 8-K as it lands

Follow RMD for push alerts, or ask the research agent what this filing means.